JP5810076B2 - 薬学的組成物 - Google Patents

薬学的組成物 Download PDF

Info

Publication number
JP5810076B2
JP5810076B2 JP2012502694A JP2012502694A JP5810076B2 JP 5810076 B2 JP5810076 B2 JP 5810076B2 JP 2012502694 A JP2012502694 A JP 2012502694A JP 2012502694 A JP2012502694 A JP 2012502694A JP 5810076 B2 JP5810076 B2 JP 5810076B2
Authority
JP
Japan
Prior art keywords
peptide
seq
antibody
aci
tau
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012502694A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012522754A5 (https=
JP2012522754A (ja
Inventor
アンドリア フェイファー
アンドリア フェイファー
アンドレアス ムース
アンドレアス ムース
ルーバン フレッド ヴァン
ルーバン フレッド ヴァン
マリア ピールグレン
マリア ピールグレン
Original Assignee
エーシー イミューン ソシエテ アノニム
エーシー イミューン ソシエテ アノニム
カトリック ユニバーシテイト ルーベン ケイユー ルーベン リサーチ アンド ディベロップメント
カトリック ユニバーシテイト ルーベン ケイユー ルーベン リサーチ アンド ディベロップメント
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42269736&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5810076(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by エーシー イミューン ソシエテ アノニム, エーシー イミューン ソシエテ アノニム, カトリック ユニバーシテイト ルーベン ケイユー ルーベン リサーチ アンド ディベロップメント, カトリック ユニバーシテイト ルーベン ケイユー ルーベン リサーチ アンド ディベロップメント filed Critical エーシー イミューン ソシエテ アノニム
Publication of JP2012522754A publication Critical patent/JP2012522754A/ja
Publication of JP2012522754A5 publication Critical patent/JP2012522754A5/ja
Application granted granted Critical
Publication of JP5810076B2 publication Critical patent/JP5810076B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
JP2012502694A 2009-04-03 2010-04-01 薬学的組成物 Active JP5810076B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09157303.0 2009-04-03
EP09157303 2009-04-03
PCT/EP2010/054418 WO2010115843A2 (en) 2009-04-03 2010-04-01 Pharmaceutical composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015129383A Division JP2015214559A (ja) 2009-04-03 2015-06-29 薬学的組成物

Publications (3)

Publication Number Publication Date
JP2012522754A JP2012522754A (ja) 2012-09-27
JP2012522754A5 JP2012522754A5 (https=) 2013-05-09
JP5810076B2 true JP5810076B2 (ja) 2015-11-11

Family

ID=42269736

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012502694A Active JP5810076B2 (ja) 2009-04-03 2010-04-01 薬学的組成物
JP2015129383A Withdrawn JP2015214559A (ja) 2009-04-03 2015-06-29 薬学的組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015129383A Withdrawn JP2015214559A (ja) 2009-04-03 2015-06-29 薬学的組成物

Country Status (28)

Country Link
US (3) US8647631B2 (https=)
EP (2) EP2413957B1 (https=)
JP (2) JP5810076B2 (https=)
KR (2) KR20150041203A (https=)
CN (2) CN102946899B (https=)
AU (1) AU2010233856B2 (https=)
BR (1) BRPI1015088B1 (https=)
CA (1) CA2757345C (https=)
CL (2) CL2011002457A1 (https=)
CO (1) CO6390113A2 (https=)
CR (1) CR20110509A (https=)
DK (2) DK2413957T3 (https=)
EC (1) ECSP11011367A (https=)
ES (2) ES2738623T3 (https=)
HU (2) HUE044981T2 (https=)
IL (1) IL215451A (https=)
MA (1) MA34120B1 (https=)
MX (1) MX2011010353A (https=)
MY (1) MY171300A (https=)
NZ (1) NZ595856A (https=)
PL (2) PL2413957T3 (https=)
PT (2) PT3097925T (https=)
RU (1) RU2582916C2 (https=)
SG (1) SG175037A1 (https=)
SI (2) SI3097925T1 (https=)
UA (1) UA107571C2 (https=)
WO (1) WO2010115843A2 (https=)
ZA (1) ZA201107776B (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US9605054B2 (en) * 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
SI2408807T1 (sl) * 2009-03-18 2021-11-30 Ac Immune Sa Postopek za terapevtsko uporabo
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
CA3239368A1 (en) * 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
EP3527220A1 (en) * 2010-08-12 2019-08-21 AC Immune S.A. Vaccine engineering
AU2013205313B2 (en) * 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
ES2548686T3 (es) * 2010-10-07 2015-10-20 Ac Immune S.A. Anticuerpos que reconocen fosfo-Tau
AR083561A1 (es) 2010-10-26 2013-03-06 Ac Immune Sa Preparacion de una construccion antigenica
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
ES2656442T3 (es) * 2011-09-19 2018-02-27 Axon Neuroscience Se Terapia basada en proteínas y diagnóstico de una patología mediada por tau en la enfermedad de Alzheimer
RU2639537C2 (ru) * 2011-10-07 2017-12-21 Ац Иммуне С.А. Фосфоспецифичные антитела, распознающие тау
JP6293731B2 (ja) * 2012-04-05 2018-03-14 エーシー イミューン エス．エー． ヒト化タウ抗体
PL2857039T3 (pl) * 2012-05-31 2020-05-18 Osaka City University Środek terapeutyczny lub środek profilaktyczny na otępienie
HK1209768A1 (en) 2012-07-03 2016-04-08 Washington University Antibodies to tau
PE20150646A1 (es) 2012-08-16 2015-05-21 Ipierian Inc Metodos de tratamiento de una tauopatia
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CN105143258B (zh) 2013-03-15 2020-06-23 Ac免疫有限公司 抗Tau抗体和使用方法
HRP20200384T1 (hr) 2013-12-20 2020-06-12 F. Hoffmann - La Roche Ag Humanizirana anti-tau(ps422) protutijela i načini uporabe
WO2015122922A1 (en) 2014-02-14 2015-08-20 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TWI664190B (zh) 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體
JP6913018B2 (ja) 2014-07-08 2021-08-04 ニューヨーク・ユニバーシティ タウイメージングリガンド、ならびにタウ異常症の診断および治療におけるそれらの使用
AR103713A1 (es) 2015-02-26 2017-05-31 Lilly Co Eli Anticuerpos contra tau y sus usos
EP4465050A3 (en) 2015-06-05 2025-06-11 Genentech, Inc. Anti-tau antibodies and methods of use
CN107810196B (zh) 2015-06-24 2021-11-05 豪夫迈·罗氏有限公司 人源化的抗-Tau(pS422)抗体和使用方法
CA2991264C (en) 2015-07-06 2023-10-10 Ucb Biopharma Sprl Tau-binding antibodies
EP3334453A4 (en) 2015-08-13 2019-02-06 New York University ANTIBODY-BASED SPECIFIC MOLECULES AND THEIR USES IN THE DIAGNOSIS AND TREATMENT OF TAUOPATHY, FOR TAU'S SPECIFIC ASP421 EPITOP
EP3496750A2 (en) 2016-08-09 2019-06-19 Eli Lilly and Company Combination therapy
CN110214184B (zh) 2016-12-01 2024-07-02 桑格摩生物治疗股份有限公司 τ蛋白调节剂以及用于其递送的方法和组合物
CN117820467A (zh) 2016-12-07 2024-04-05 基因泰克公司 抗tau抗体和使用方法
MA48595A (fr) 2016-12-07 2020-03-18 Ac Immune Sa Anticorps anti-tau et leurs méthodes d'utilisation
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
EP3697814A1 (en) 2017-10-16 2020-08-26 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
KR102710762B1 (ko) 2017-10-25 2024-09-25 얀센 파마슈티칼즈, 인코포레이티드 인산화 타우 펩티드의 조성물 및 이의 용도
CA3107788A1 (en) 2018-07-31 2020-02-06 Eli Lilly And Company Combination of anti-tau antibody and oga inhibitor for treatment of diseases characterized by aberrant tau aggregation
KR20210070344A (ko) 2018-10-02 2021-06-14 상가모 테라퓨틱스, 인코포레이티드 타우 단백질의 조정을 위한 방법 및 조성물
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
AU2020219804A1 (en) * 2019-02-08 2021-08-19 Ac Immune S.A. Method of safe administration of phosphorylated Tau peptide vaccine
EA202192891A1 (ru) 2019-04-24 2022-02-04 Янссен Фармасьютикалз, Инк. Гетерологичное введение анти-тау вакцин
GB2585252A (en) 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
CA3183835A1 (en) 2020-06-25 2021-12-30 Jeanne E. Baker High affinity antibodies targeting tau phosphorylated at serine 413
US20240101654A1 (en) * 2020-12-29 2024-03-28 Neurimmune Ag Human anti-tau antibodies
WO2023161528A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN
KR102856378B1 (ko) * 2022-09-30 2025-09-08 주식회사 젬백스앤카엘 4r 타우병증의 치료 또는 예방용 펩티드
WO2025109524A1 (en) 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811310A (en) * 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
DE69318420T2 (de) * 1992-12-14 1999-01-28 Naamloze Vennootschap Innogenetics S.A., Gent Monoklonale antikörper gegen das mikrotubulusassoziierte tauprotein,hybridomen, die diese antikörper sezernieren, antigenerkennung durch diese monoklonalen antikörper und deren verwendung
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US20020086009A1 (en) * 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
WO1998022120A1 (en) * 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
KR20010032753A (ko) * 1997-12-03 2001-04-25 온토제니, 인코오포레이티드 소수적으로 개질된 단백질 조성물 및 방법
CA2415919A1 (en) 2000-07-11 2002-01-17 Molecular Geriatrics Corporation Reagents and methods for identification of binding agents
EP1585520A1 (en) 2002-12-24 2005-10-19 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US8663650B2 (en) * 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US20050261475A1 (en) * 2004-02-13 2005-11-24 Harvard Medical School Solid-phase capture-release-tag methods for phosphoproteomic analyses
US7238788B2 (en) * 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
CA2633399C (en) 2005-12-12 2016-01-26 Ac Immune S.A. Therapeutic vaccine
WO2007068105A1 (en) * 2005-12-12 2007-06-21 Robarts Research Institute Method of diagnosing amyotrophic lateral sclerosis
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008140639A2 (en) 2007-02-08 2008-11-20 Oligomerix, Inc. Biomarkers and assays for alzheimer's disease
JPWO2009051220A1 (ja) 2007-10-19 2011-03-03 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
SI2408807T1 (sl) * 2009-03-18 2021-11-30 Ac Immune Sa Postopek za terapevtsko uporabo
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
CA3239368A1 (en) 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
NZ598356A (en) 2009-07-30 2014-06-27 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof

Also Published As

Publication number Publication date
SI2413957T1 (sl) 2016-12-30
EP2413957B1 (en) 2016-07-27
CN102946899B (zh) 2016-01-20
EP3097925A1 (en) 2016-11-30
HK1164127A1 (en) 2012-09-21
CO6390113A2 (es) 2012-02-29
ES2738623T3 (es) 2020-01-24
NZ595856A (en) 2014-05-30
JP2012522754A (ja) 2012-09-27
RU2582916C2 (ru) 2016-04-27
SI3097925T1 (sl) 2019-11-29
WO2010115843A2 (en) 2010-10-14
MX2011010353A (es) 2011-12-06
AU2010233856A1 (en) 2011-10-27
KR101770436B1 (ko) 2017-08-23
CA2757345A1 (en) 2010-10-14
HUE030428T2 (en) 2017-05-29
BRPI1015088B1 (pt) 2021-06-29
RU2011144307A (ru) 2013-05-10
HUE044981T2 (hu) 2019-12-30
HK1231408A1 (en) 2017-12-22
KR20150041203A (ko) 2015-04-15
MA34120B1 (fr) 2013-04-03
US20120183599A1 (en) 2012-07-19
CA2757345C (en) 2020-04-14
US20150259406A1 (en) 2015-09-17
KR20120034609A (ko) 2012-04-12
JP2015214559A (ja) 2015-12-03
MY171300A (en) 2019-10-07
US8647631B2 (en) 2014-02-11
ES2595371T3 (es) 2016-12-29
PT3097925T (pt) 2019-07-23
BRPI1015088A2 (pt) 2016-06-28
ECSP11011367A (es) 2012-03-30
CN105524160A (zh) 2016-04-27
DK2413957T3 (en) 2016-10-10
IL215451A0 (en) 2011-12-29
CL2011002457A1 (es) 2012-03-16
WO2010115843A3 (en) 2010-12-02
CN102946899A (zh) 2013-02-27
US20140255412A1 (en) 2014-09-11
DK3097925T3 (da) 2019-08-05
AU2010233856B2 (en) 2014-04-10
IL215451A (en) 2016-05-31
EP2413957A2 (en) 2012-02-08
CN105524160B (zh) 2019-07-19
EP3097925B1 (en) 2019-06-12
CR20110509A (es) 2012-02-09
ZA201107776B (en) 2014-03-26
CL2013002888A1 (es) 2014-09-05
UA107571C2 (xx) 2015-01-26
PT2413957T (pt) 2016-09-30
SG175037A1 (en) 2011-11-28
PL2413957T3 (pl) 2017-01-31
PL3097925T3 (pl) 2020-02-28
AU2010233856A2 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
JP5810076B2 (ja) 薬学的組成物
US9289488B2 (en) Vaccine engineering
CA2632822C (en) A beta 1-42 specific monoclonal antibodies with therapeutic properties
CN102428101B (zh) 用于治疗用途的方法
AU2012244075B2 (en) A beta 1-42 specific monoclonal antibodies with therapeutic properties
HK1231408B (en) Pharmaceutical composition
HK1164127B (en) Pharmaceutical composition
AU2015201763A1 (en) A beta 1-42 specific monoclonal antibodies with therapeutic properties
JP2007527870A (ja) 超分子コンストラクトを含む方法および組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130321

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141112

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150325

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150629

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150722

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150827

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150914

R150 Certificate of patent or registration of utility model

Ref document number: 5810076

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250